We have gathered recently published GWAS summary-level statistics to explore the causal relationships between genetically predicted IL6R inhibition and 15 diseases, including COVID-19, rheumatoid arthritis, asthma, asthmatic pneumonia, cor pulmonale, non-small cell lung cancer, small cell lung cancer, Parkinson’s, Alzheimer’s disease, ulcerative colitis, Crohn’s disease, systemic lupus erythematosus, and types 1 and 2 diabetes through drug-target MR analysis. The gene discussed is IL6R; the disease is COVID-19.